A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions ... the increasing incidence of diabetes, more options for oral antidiabetic agents are warranted.

WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic ...

The talks around drugs including Novo Nordisk’s Wegovy, GSK’s Trelegy Ellipta, and Pfizer’s Xtandi will set Medicare prices that go into effect in 2027.